Akero Therapeutics, Inc.
US ˙ NasdaqGS ˙ US00973Y1082

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Versant Ventures VI GP, L.P.. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Versant Ventures VI GP, L.P. har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
10% Owner 856.157
US:LVTX / LAVA Therapeutics N.V. 10% Owner 532.870
US:GLUE / Monte Rosa Therapeutics, Inc. 10% Owner 1.573.453
US:TPST / Tempest Therapeutics, Inc. 10% Owner 209.941
10% Owner 148.312
US:OYST / Oyster Point Pharma Inc 10% Owner 0
US:IPSC / Century Therapeutics, Inc. 10% Owner 11.452.014
US:RPTX / Repare Therapeutics Inc. 10% Owner 0
10% Owner 0
US:AKRO / Akero Therapeutics, Inc. 10% Owner 2.846.941
US:PASG / Passage Bio, Inc. 10% Owner 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Versant Ventures VI GP, L.P.. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb AKRO / Akero Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AKRO / Akero Therapeutics, Inc. Insider Trades
Insidersalg AKRO / Akero Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AKRO / Akero Therapeutics, Inc. Insider Trades
Insiderkøb GLUE / Monte Rosa Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-06-28 GLUE Versant Venture Capital VI, L.P. 157.895 19,0000 157.895 19,0000 3.000.005 67 42.21 3.664.743 122,16

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insidersalg GLUE / Monte Rosa Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-10-29 GLUE Versant Venture Capital VI, L.P. 52.305 9,0815 52.305 9,0815 475.008 197 3.7000 -281.478 -59,26
2024-10-29 GLUE Versant Venture Capital VI, L.P. 15.600 9,4098 15.600 9,4098 146.793
2024-10-28 GLUE Versant Venture Capital VI, L.P. 89.990 9,6593 89.990 9,6593 869.240
2024-09-20 GLUE Versant Venture Capital VI, L.P. 1.132.566 6,5296 1.132.566 6,5296 7.395.203
2024-09-13 GLUE Versant Venture Capital VI, L.P. 9.269 6,1603 9.269 6,1603 57.100
2024-09-12 GLUE Versant Venture Capital VI, L.P. 16.047 6,0017 16.047 6,0017 96.309
2024-09-11 GLUE Versant Venture Capital VI, L.P. 541.897 6,0000 541.897 6,0000 3.251.382

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insiderkøb IPSC / Century Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-06-22 IPSC Versant Venture Capital VI, L.P. 100.000 20,0000 100.000 20,0000 2.000.000 0

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IPSC / Century Therapeutics, Inc. Insider Trades
Insidersalg IPSC / Century Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IPSC / Century Therapeutics, Inc. Insider Trades
Insiderkøb LVTX / LAVA Therapeutics N.V. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insidersalg LVTX / LAVA Therapeutics N.V. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2025-09-18 LVTX Versant Venture Capital VI, L.P. 366.111 1,4418 366.111 1,4418 527.859 0 1.4700 10.325 1,96
2025-09-18 LVTX Versant Venture Capital VI, L.P. 228.791 1,4418 228.791 1,4418 329.871
2025-09-17 LVTX Versant Venture Capital VI, L.P. 362.806 1,4892 362.806 1,4892 540.291
2025-09-17 LVTX Versant Venture Capital VI, L.P. 226.726 1,4892 226.726 1,4892 337.640
2025-09-16 LVTX Versant Venture Capital VI, L.P. 307.707 1,5332 307.707 1,5332 471.776
2025-09-16 LVTX Versant Venture Capital VI, L.P. 192.293 1,5332 192.293 1,5332 294.824

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LVTX / LAVA Therapeutics N.V. Insider Trades
Insiderkøb PASG / Passage Bio, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-03-03 PASG Versant Venture Capital VI, L.P. 225.000 18,0000 11.250 360,0000 4.050.000 112 36.07 -3.644.212 -89,98

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PASG / Passage Bio, Inc. Insider Trades
Insidersalg PASG / Passage Bio, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PASG / Passage Bio, Inc. Insider Trades
Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2022-06-03 RPTX Versant Ventures V, LLC 250.000 12,2517 250.000 12,2517 3.062.925 311 8.6300 -905.425 -29,56
2022-06-03 RPTX Versant Ventures V, LLC 438.795 12,2517 438.795 12,2517 5.375.985
2022-06-03 RPTX Versant Ventures V, LLC 13.199 12,2517 13.199 12,2517 161.710
2022-06-03 RPTX Versant Ventures V, LLC 14.611 12,2517 14.611 12,2517 179.010
2022-06-03 RPTX Versant Ventures V, LLC 33.395 12,2517 33.395 12,2517 409.146

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insiderkøb TPST / Tempest Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AKRO / Akero Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insidersalg TPST / Tempest Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AKRO / Akero Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-08-12 TPST Versant Venture Capital VI, L.P. 387.999 1,1005 29.846 14,3065 426.993 239 0.5006 -412.051 -96,50
2024-08-08 TPST Versant Venture Capital VI, L.P. 400.000 1,3501 30.769 17,5513 540.040

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Versant Ventures VI GP, L.P. som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -132 856.157 -0,02 43,30 -5.716 37.071.598
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -268 1.183.543 -0,02 43,30 -11.604 51.247.412
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -20.148 856.289 -2,30 43,00 -866.441 36.823.681
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -40.907 1.183.811 -3,34 43,00 -1.759.156 50.908.371
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -24.370 876.437 -2,71 41,59 -1.013.568 36.451.716
2025-09-22 2025-09-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -49.479 1.224.718 -3,88 41,59 -2.057.871 50.937.001
2025-09-18 2025-09-18 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -228.791 532.870 -30,04 1,44 -329.871 768.292
2025-09-18 2025-09-18 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -366.111 2.370.533 -13,38 1,44 -527.859 3.417.834
2025-09-18 2025-09-17 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -226.726 761.661 -22,94 1,49 -337.640 1.134.266
2025-09-18 2025-09-17 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -362.806 2.736.644 -11,71 1,49 -540.291 4.075.410
2025-09-18 2025-09-16 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -192.293 988.387 -16,29 1,53 -294.824 1.515.395
2025-09-18 2025-09-16 4 LVTX LAVA Therapeutics NV
Common Stock
S - Sale -307.707 3.099.450 -9,03 1,53 -471.776 4.752.077
2025-08-26 2025-08-26 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -1.707 900.807 -0,19 39,50 -67.430 35.583.858
2025-08-26 2025-08-26 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -3.465 1.274.197 -0,27 39,50 -136.875 50.333.585
2025-08-26 2025-08-26 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -21.661 902.514 -2,34 38,97 -844.224 35.174.942
2025-08-26 2025-08-26 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -43.978 1.277.662 -3,33 38,97 -1.714.016 49.796.110
2025-08-26 2025-08-25 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -1.058 924.175 -0,11 39,92 -42.237 36.894.175
2025-08-26 2025-08-25 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -2.149 1.321.640 -0,16 39,92 -85.791 52.761.455
2025-08-26 2025-08-25 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -24.760 925.233 -2,61 39,53 -978.651 36.570.297
2025-08-26 2025-08-25 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -50.270 1.323.789 -3,66 39,53 -1.986.947 52.323.422
2025-08-26 2025-08-22 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -2.809 949.993 -0,29 40,59 -114.017 38.560.121
2025-08-26 2025-08-22 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -5.668 1.374.059 -0,41 40,59 -230.064 55.772.917
2025-08-26 2025-08-22 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -10.076 952.802 -1,05 40,03 -403.339 38.140.378
2025-08-26 2025-08-22 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -20.493 1.379.727 -1,46 40,03 -820.329 55.230.058
2025-08-19 2025-08-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -15.085 962.878 -1,54 38,56 -581.694 37.129.635
2025-08-19 2025-08-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -30.628 1.400.220 -2,14 38,56 -1.181.049 53.994.023
2025-08-19 2025-08-15 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -69.949 977.963 -6,68 39,50 -2.762.986 38.629.538
2025-08-19 2025-08-15 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -145.051 1.430.848 -9,20 39,50 -5.729.514 56.518.496
2025-07-14 2025-07-10 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -191.376 1.575.899 -10,83 34,00 -6.506.784 53.580.566
2025-07-01 2025-06-27 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -200.000 1.767.275 -10,17 30,46 -6.093.000 53.840.033
2025-06-20 2025-06-20 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -133.924 1.967.275 -6,37 30,25 -4.051.201 59.510.069
2025-06-20 2025-06-20 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -100.877 1.047.912 -8,78 30,35 -3.061.617 31.804.129
2025-06-20 2025-06-18 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -100.000 1.148.789 -8,01 29,95 -2.995.000 34.406.231
2025-06-12 2025-06-10 4 LENZ LENZ Therapeutics, Inc.
Common Stock
S - Sale -350.000 1.248.789 -21,89 29,00 -10.150.000 36.214.881
2025-02-06 3 LVTX LAVA Therapeutics NV
Common Shares
3.407.157
2025-02-06 3 LVTX LAVA Therapeutics NV
Common Shares
1.180.680
2024-10-30 2024-10-29 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -15.600 1.573.453 -0,98 9,41 -146.793 14.805.878
2024-10-30 2024-10-29 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -52.305 1.589.053 -3,19 9,08 -475.008 14.430.985
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -5.454 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 5.454 5.454
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -5.499 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 5.499 5.499
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -366.590 1.641.358 -18,26
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -17.595 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 17.595 17.595
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -20.397 0 -100,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other 20.397 20.397
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
J - Other -1.019.867 4.079.469 -20,00
2024-10-30 2024-10-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -89.990 2.007.948 -4,29 9,66 -869.240 19.395.372
2024-09-24 2024-09-20 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -1.132.566 5.099.336 -18,17 6,53 -7.395.203 33.296.624
2024-09-13 2024-09-13 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -9.269 6.231.902 -0,15 6,16 -57.100 38.390.386
2024-09-13 2024-09-12 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -16.047 6.241.171 -0,26 6,00 -96.309 37.457.636
2024-09-13 2024-09-11 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
S - Sale -541.897 6.257.218 -7,97 6,00 -3.251.382 37.543.308
2024-08-12 2024-08-12 4 TPST Tempest Therapeutics, Inc.
Common Stock
S - Sale -387.999 209.941 -64,89 1,10 -426.993 231.040
2024-08-12 2024-08-08 4 TPST Tempest Therapeutics, Inc.
Common Stock
S - Sale -400.000 597.940 -40,08 1,35 -540.040 807.279
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 148.312 148.312
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 2.531 2.531
2024-04-11 2024-04-09 4 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
C - Conversion 391.785 391.785
2024-04-04 3 CTNM Contineum Therapeutics, Inc.
Class A Common Stock
375.535
2024-03-25 2024-03-21 4 LENZ LENZ Therapeutics, Inc.
Common Stock
J - Other 598.203 842.162 245,21
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -1.003.658 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -2.465 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -414.607 0 -100,00
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock
U - Other -2.236.888 0 -100,00
2022-08-11 2022-08-09 4 IPSC Century Therapeutics, Inc.
Common Stock
J - Other X -364.800 11.452.014 -3,09
2022-08-11 2022-08-09 4 IPSC Century Therapeutics, Inc.
Common Stock
S - Sale X -550.000 11.816.814 -4,45 13,03 -7.166.610 153.975.450
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -10.099 0 -100,00
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 10.099 10.099
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -46.753 64.731 -41,94
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -141.103 0 -100,00
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.419 141.103 3,23
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -20.454 28.322 -41,93
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 3.992 136.684 3,01
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -18.478 25.587 -41,93
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 132.692 132.692
2022-06-07 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -614.315 850.560 -41,94
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -33.395 111.484 -23,05 12,25 -409.146 1.365.869
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -14.611 48.776 -23,05 12,25 -179.010 597.589
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -13.199 44.065 -23,05 12,25 -161.710 539.871
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -438.795 1.464.875 -23,05 12,25 -5.375.985 17.947.209
2022-06-07 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -250.000 2.344.451 -9,64 12,25 -3.062.925 28.723.510
2022-02-02 2022-01-31 4 IPSC Century Therapeutics, Inc.
Common Stock
J - Other -178.996 12.366.814 -1,43
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -1.261 2.465 -33,84
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -51.556 0 -100,00
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 51.556 51.556
2022-01-07 2022-01-05 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -200.213 414.607 -32,56
2021-12-28 2021-12-23 4 IPSC Century Therapeutics, Inc.
Common Stock
J - Other X -371.004 12.545.810 -2,87
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -1.261 3.726 -25,29
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -51.556 0 -100,00
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 51.556 51.556
2021-12-23 2021-12-21 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -200.213 614.820 -24,57
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -1.531 4.987 -23,49 15,09 -23.109 75.273
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -242.943 815.033 -22,96 15,09 -3.666.957 12.302.027
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -1.912 6.518 -22,68 14,63 -27.978 95.376
2021-10-20 2021-10-18 4 OYST Oyster Point Pharma, Inc.
Common Stock
S - Sale X -303.614 1.057.976 -22,30 14,63 -4.442.693 15.481.045
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -2.260 0 -100,00
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 2.260 2.260
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -2.279 0 -100,00
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 2.279 2.279
2021-08-09 2021-08-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -152.071 231.211 -39,68
2021-07-06 3 TPST Tempest Therapeutics, Inc.
Common Stock
997.940
2021-07-06 3 TPST Tempest Therapeutics, Inc.
Common Stock
1.171.094
2021-07-06 3 TPST Tempest Therapeutics, Inc.
Common Stock
7.377
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Series B Preferred Stock
C - Conversion -3.715.415 0 -100,00
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Series A Preferred Stock
C - Conversion -30.019.945 0 -100,00
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Common Stock
P - Purchase 180.000 1.707.719 11,78 17,00 3.060.000 29.031.223
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Common Stock
C - Conversion 1.527.719 1.527.719
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Common Stock
C - Conversion 12.343.727 14.708.398 522,01
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series C convertible preferred stock
C - Conversion -2.699.328 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock
C - Conversion -4.150.000 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock
C - Conversion -3.000.000 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series A convertible preferred stock
C - Conversion -20.004.280 0 -100,00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
P - Purchase 157.895 2.097.938 8,14 19,00 3.000.005 39.860.822
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
C - Conversion 1.940.043 1.940.043
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
C - Conversion 6.515.869 6.799.115 2.300,43
2021-06-24 3 GRPH Graphite Bio, Inc.
Common Stock
2.364.671
2021-06-23 2021-06-22 4 IPSC Century Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.545.125 0 -100,00
2021-06-23 2021-06-22 4 IPSC Century Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -25.000.000 0 -100,00
2021-06-23 2021-06-22 4 IPSC Century Therapeutics, Inc.
Common Stock
P - Purchase 100.000 714.095 16,28 20,00 2.000.000 14.281.900
2021-06-23 2021-06-22 4 IPSC Century Therapeutics, Inc.
Common Stock
C - Conversion 614.095 614.095
2021-06-23 2021-06-22 4 IPSC Century Therapeutics, Inc.
Common Stock
C - Conversion 9.936.011 12.916.814 333,33
2021-06-23 3 GLUE Monte Rosa Therapeutics, Inc.
Common Stock
283.246
2021-06-17 3 IPSC Century Therapeutics, Inc.
Common Stock
2.980.803
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.119 0 -100,00
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.119 1.119
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.128 0 -100,00
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.128 1.128
2021-06-03 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -75.000 383.282 -16,37
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -2.018 8.430 -19,31
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -82.486 0 -100,00
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 82.486 82.486
2021-05-14 2021-05-12 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -320.340 1.361.590 -19,05
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -3.473 0 -100,00
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 3.473 3.473
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -16.079 144.879 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -48.528 0 -100,00
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.520 48.528 3,23
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -7.035 63.387 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.373 47.008 3,01
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -6.355 57.264 -9,99
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 45.635 45.635
2021-05-07 2021-05-05 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -211.277 1.903.670 -9,99
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -1.990 10.448 -16,00
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -82.491 0 -100,00
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 82.491 82.491
2021-03-30 2021-03-26 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -320.368 1.681.930 -16,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -5.607 0 -100,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 5.607 5.607
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other -6.500 0 -100,00
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other 6.500 6.500
2021-02-19 2021-02-17 4 OYST Oyster Point Pharma, Inc.
Common Stock
J - Other X -325.000 2.236.888 -12,69
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 458.282 -9,84
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.176 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.176 5.176
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -6.000 0 -100,00
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 6.000 6.000
2021-02-18 2021-02-16 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -300.000 2.594.451 -10,36
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 508.282 -8,96
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.313 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.313 4.313
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.000 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.000 5.000
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -250.000 2.894.451 -7,95
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.328 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.328 4.328
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -20.037 160.958 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -60.472 0 -100,00
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.893 60.472 3,23
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -8.766 70.422 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.711 58.579 3,01
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -7.919 63.619 -11,07
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 56.868 56.868
2021-02-02 2021-01-29 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -263.278 2.114.947 -11,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -745 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 745 745
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -751 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 751 751
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -50.000 558.282 -8,22
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -4.744 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 4.744 4.744
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -5.500 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 5.500 5.500
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -275.000 3.144.451 -8,04
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -1.388 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.388 1.388
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -11.688 180.995 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other -35.276 0 -100,00
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 1.105 35.276 3,23
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -5.113 79.188 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 998 34.171 3,01
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -4.620 71.538 -6,07
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 33.173 33.173
2021-01-19 2021-01-14 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -153.579 2.378.225 -6,07
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -21.707 192.683 -10,13
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -9.497 84.301 -10,12
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -8.579 76.158 -10,12
2020-12-17 2020-12-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -285.217 2.531.804 -10,12
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Simple Agreement for Future Equity
C - Conversion -333.333 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.245.330 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.745.458 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -14.452.795 0 -100,00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 577.544 577.544
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 3.176.507 3.176.507
2020-07-10 2020-01-09 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -16.527 2.846.941 -0,58 20,21 -334.011 57.536.678
2020-07-10 2020-01-08 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.368 2.863.468 -0,78 19,80 -442.886 56.696.666
2020-07-10 2020-01-07 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -14.162 2.885.836 -0,49 20,05 -283.948 57.861.012
2020-07-10 2020-01-06 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -42.323 2.899.998 -1,44 19,93 -843.497 57.796.960
2020-07-10 2020-01-06 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -6.101 2.942.321 -0,21 18,32 -111.770 53.903.321
2020-07-10 2020-01-06 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.968 2.948.422 -0,17 17,68 -87.834 52.128.101
2020-07-10 2020-01-03 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -100 2.953.390 0,00 20,27 -2.027 59.865.215
2020-07-10 2020-01-03 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.100 2.953.490 -0,10 19,18 -59.458 56.647.938
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -11.803 0 -100,00
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
J - Other 11.803 11.803
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -13.683 0 -100,00
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
J - Other 13.683 13.683
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -684.143 2.956.590 -18,79
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.000 3.640.733 -0,03 22,17 -22.170 80.715.051
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.900 3.641.733 -0,11 21,20 -82.680 77.204.740
2020-07-10 2020-01-02 4/A AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.952 3.645.633 -0,30 19,89 -217.835 72.511.640
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -458.282 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -875.568 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -3.350 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -3.708 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -8.475 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -111.361 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -2.443.883 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -61.791 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -68.398 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -156.335 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -2.054.198 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
P - Purchase 100.000 3.419.451 3,01 20,00 2.000.000 68.389.020
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
P - Purchase 150.000 608.282 32,73 20,00 3.000.000 12.165.640
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 458.282 458.282
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 875.568 3.319.451 35,83
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 3.350 84.737 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 3.708 93.798 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 8.475 214.390 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 111.361 2.817.021 4,12
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 2.443.883 2.443.883
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 61.791 81.387 315,32
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 68.398 90.090 315,31
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 156.335 205.915 315,32
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 2.054.198 2.705.660 315,32
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
1.393.792
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
791.910
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
764.022
2020-06-18 3 RPTX Repare Therapeutics Inc.
Common Shares
761.926
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series B Preferred Stock
C - Conversion -708.352 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-2 Preferred Stock
C - Conversion -1.049.175 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-1 Preferred Stock
C - Conversion -2.977.242 0 -100,00
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
P - Purchase 225.000 933.352 31,76 18,00 4.050.000 16.800.336
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 708.352 708.352
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 1.049.175 4.026.417 35,24
2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock
C - Conversion 2.977.242 2.977.242
2020-01-21 2020-01-21 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -17.849 3.092.698 -0,57 22,39 -399.639 69.245.508
2020-01-21 2020-01-21 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -8.091 3.110.547 -0,26 21,78 -176.222 67.747.714
2020-01-21 2020-01-17 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -11.103 3.118.638 -0,35 20,09 -223.059 62.653.437
2020-01-21 2020-01-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.489 3.129.741 -0,71 19,72 -443.483 61.718.493
2020-01-15 2020-01-15 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -7.511 3.152.230 -0,24 19,73 -148.192 62.193.498
2020-01-15 2020-01-14 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.307 3.159.741 -0,39 20,00 -246.140 63.194.820
2020-01-15 2020-01-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -83 3.172.048 0,00 20,84 -1.730 66.105.480
2020-01-15 2020-01-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -11.593 3.172.131 -0,36 20,16 -233.715 63.950.161
2020-01-15 2020-01-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -19.343 3.183.724 -0,60 20,10 -388.794 63.992.852
2020-01-09 2020-01-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -16.527 3.203.067 -0,51 20,21 -334.011 64.733.984
2020-01-09 2020-01-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -22.368 3.219.594 -0,69 19,80 -442.886 63.747.961
2020-01-09 2020-01-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -14.162 3.241.962 -0,43 20,05 -283.948 65.001.338
2020-01-06 2020-01-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -42.323 3.256.124 -1,28 19,93 -843.497 64.894.551
2020-01-06 2020-01-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -6.101 3.298.447 -0,18 18,32 -111.770 60.427.549
2020-01-06 2020-01-06 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.968 3.304.548 -0,15 17,68 -87.834 58.424.409
2020-01-06 2020-01-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -100 3.309.516 0,00 20,27 -2.027 67.083.889
2020-01-06 2020-01-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.100 3.309.616 -0,09 19,18 -59.458 63.478.435
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -11.803 0 -100,00
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
J - Other 11.803 11.803
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -13.683 0 -100,00
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
J - Other 13.683 13.683
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
J - Other -684.143 3.312.716 -17,12
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.000 3.996.859 -0,03 22,17 -22.170 88.610.364
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.900 3.997.859 -0,10 21,20 -82.680 84.754.611
2020-01-06 2020-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.952 4.001.759 -0,27 19,89 -217.835 79.594.987
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock
C - Conversion -566.158 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock
C - Conversion -495.388 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.941.500 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -1.654.359 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock
C - Conversion -10.420 0 -100,00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 437.500 1.003.658 77,28 16,00 7.000.000 16.058.528
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 566.158 566.158
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 125.000 2.561.888 5,13 16,00 2.000.000 40.990.208
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 495.388 2.436.888 25,52
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 1.941.500 1.941.500
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
P - Purchase 27.500 2.002.298 1,39 16,00 440.000 32.036.768
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 1.654.359 1.974.798 516,28
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
C - Conversion 10.420 12.438 516,35
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
324.475
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share
642.896
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)